24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
BORTELIEVA 2 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | BORTELIEVA 2 MG |
|---|---|
| Composition | Bortezomib Injection IP 2mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
BORTELIEVA 2 MG (Bortezomib Injection IP 2mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
BORTELIEVA 2 MG (Bortezomib Injection IP 2 mg) is a prescription anticancer medicine containing Bortezomib 2 mg, a targeted therapy primarily used in the treatment of Multiple Myeloma and Mantle Cell Lymphoma (MCL). It belongs to a class of medicines known as proteasome inhibitors, which help destroy cancer cells by interfering with essential cellular processes required for their growth and survival.
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell responsible for producing antibodies. When plasma cells become abnormal and multiply uncontrollably, they can damage bones, kidneys, and the immune system. Mantle Cell Lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that affects B-lymphocytes within the lymphatic system. BORTELIEVA 2 MG is specifically designed to target these cancer cells and help slow disease progression.
Bortezomib works by blocking the activity of proteasomes, specialized structures inside cells that remove damaged or unnecessary proteins. Cancer cells rely heavily on proteasomes to maintain their rapid growth. By inhibiting proteasome activity, Bortezomib causes protein accumulation within cancer cells, leading to cellular stress, disruption of cancer cell function, and eventual cell death.
BORTELIEVA 2 MG is commonly prescribed for:
The medicine may be administered alone or in combination with other anticancer agents depending on the patient's condition, treatment history, and clinical requirements.
Manufactured under stringent pharmaceutical quality standards, BORTELIEVA 2 MG is designed to provide consistent quality, safety, and therapeutic effectiveness. The injection should only be administered by qualified healthcare professionals experienced in oncology and hematology treatment.
Patients receiving Bortezomib therapy often require routine blood tests, liver function monitoring, kidney assessments, neurological evaluations, and regular clinical follow-up to ensure safe and effective treatment.
Due to its established effectiveness in managing blood cancers, BORTELIEVA 2 MG remains an important component of modern cancer treatment protocols worldwide.
BORTELIEVA 2 MG (Bortezomib Injection IP 2 mg) is primarily used for the treatment and management of specific blood cancers.
The medicine is widely used in patients diagnosed with newly diagnosed, relapsed, or refractory multiple myeloma.
Bortezomib is used in selected patients with mantle cell lymphoma to help control disease progression.
The medicine may be prescribed when blood cancers return after previous treatment.
BORTELIEVA is frequently combined with other anticancer medicines to improve treatment outcomes.
The medicine supports comprehensive treatment strategies for complex blood cancers.
It plays an important role in modern targeted cancer therapy protocols.
Bortezomib belongs to a class of medicines known as Proteasome Inhibitors.
BORTELIEVA works by:
This targeted mechanism helps control disease progression and improve treatment outcomes in patients with blood cancers.
Like all anticancer medicines, BORTELIEVA 2 MG may cause side effects in some patients. Side effects vary depending on treatment duration, dosage, and individual response.
Weakness and tiredness are commonly reported during therapy.
Patients may experience mild to moderate nausea.
Some individuals may develop episodes of vomiting.
Digestive disturbances and loose stools may occur.
Some patients may experience difficulty passing stools.
Reduced appetite may affect nutritional intake.
Mild fever may occur during treatment.
Patients may experience tingling, numbness, burning sensations, or pain in the hands and feet.
The medicine may reduce:
This may increase the risk of infections, anemia, and bleeding complications.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of BORTELIEVA 2 MG (Bortezomib Injection IP 2 mg) should always be determined by a qualified oncologist or hematologist.
Treatment schedules vary according to the diagnosed condition.
Dosage is commonly calculated according to body size.
Prior therapies may influence treatment planning.
Laboratory test results help determine treatment suitability.
Doctors may adjust therapy based on effectiveness and patient tolerance.
Before receiving treatment, patients should inform their doctor if they have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only receive this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of Multiple Myeloma and Mantle Cell Lymphoma.
Bortezomib is a proteasome inhibitor that disrupts cancer cell survival mechanisms and promotes cancer cell death.
It is considered a targeted anticancer therapy and is commonly used in oncology treatment programs.
Yes, it is frequently administered as part of combination treatment regimens.
Yes, some patients may experience peripheral neuropathy, including tingling, numbness, or pain in the hands and feet.
Yes, the medicine may lower blood cell counts, requiring regular laboratory monitoring.
Yes, doctors typically recommend blood tests, liver and kidney assessments, and neurological evaluations throughout therapy.
Yes, this medicine should only be administered by qualified healthcare professionals experienced in oncology, hematology, and cancer treatment.